Quinoline

Quinoline

SCHEMBL483565

N.c1ccc2ncccc2c1

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.94
NPC1 O15118 2/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 1/20 0.56
CYP3A4 P08684 3/20 0.54
MAPT P10636 4/20 0.52
HTT P42858 3/20 0.52
KDM4E B2RXH2 3/20 0.52
CASP1 P29466 2/20 0.52
TP53 P04637 2/20 0.52
HSP90AA1 P07900 2/20 0.52
TSHR P16473 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
CASP7 P55210 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
NR4A2 P43354 1/20 0.52
HSP90AB1 P08238 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL29558745 1.00 ALDH1A1 (0.94) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL5714730 1.00 ALDH1A1 (0.94) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL2790221 1.00 ALDH1A1 (0.94) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL28067914 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL28099332 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL28138908 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL27657334 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL28089949 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL28162459 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4
Quinoline SCHEMBL28131670 0.97 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119529141-A Preparation method of quinoline amino binuclear metal titanium zirconium hafnium catalyst and application of catalyst in olefin polymerization 青岛科技大学 2025-02-28 CN claimed
CN-119390880-A Preparation method of ultrahigh molecular weight propylene-based elastomer 青岛科技大学 2025-02-07 CN claimed
US-20230390406-A1 Star Polymer Drug Conjugates BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. 2023-12-07 US claimed
EP-4228701-A1 STAR POLYMER DRUG CONJUGATES Vaccitech North America, Inc. (US) 2023-08-23 EP claimed
CN-109771657-B High-molecular antitumor drug bonded with vascular blocking agent and immunomodulator and preparation method thereof 湘潭大学 2022-06-24 CN claimed
WO-2022086853-A1 STAR POLYMER DRUG CONJUGATES AVIDEA TECHNOLOGIES, INC. (US) 2022-04-28 WO claimed
CN-111909163-B Quinolamine compound with IDO1 inhibition function and preparation method thereof 南开大学 2022-02-01 CN claimed
CN-111777608-B Novel plant modified quinoline quaternary ammonium salt compound, preparation method and application 湖北精瑜材料有限公司 2021-08-03 CN claimed
CN-112795375-A Controllable release solid acid material and preparation method and application thereof 南京科匠新材料技术开发有限公司 2021-05-14 CN claimed
CN-108707144-B Chiral quinoline amine compound and preparation method and application thereof 浙江大学 2020-11-24 CN claimed
US-20050226878-A1 Therapeutic combinations and methods including IRM compounds 3M INNOVATIVE PROPERTIES COMPANY 2005-10-13 US claimed
CN-1681470-A Agent for dyeing keratinous fibres HENKEL KGAA (DE) 2005-10-12 CN claimed
WO-2004080292-A2 METHOD OF TATTOO REMOVAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-09-23 WO claimed
US-20040181211-A1 Method of tattoo removal 3M INNOVATIVE PROPERTIES COMPANY 2004-09-16 US claimed
WO-2004071459-A2 METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR 8 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-08-26 WO claimed
US-20040162309-A1 Methods and compositions related to IRM compounds and toll-like receptor 8 3M INNOVATIVE PROPERTIES COMPANY 2004-08-19 US claimed
EP-1100802-B1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2003-09-24 EP claimed
CN-1164185-A Lyophilized preparation providing reversibly thermogelling water-base medicinal composition WAKAMOTO PHARMA CO LTD (JP) 1997-11-05 CN claimed
US-5084210-A A mixture of a cyclic quaternary amine, a surfactant, an acety lenic alcohol and a solvent effective to inhibit oxidation CHEMLINK INCORPORATED (US) 1992-01-28 US claimed
US-4691062-A Process for the production of 4-chloro-butanals DEGUSSA AKTIENGESELLSCHAFT (DE) 1987-09-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390406-A1 Star Polymer Drug Conjugates CCND3, CCND2, DRD3 ALDH1A1 1987/4885NPC1 1748/4885POLB 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.